Adverse effects in therapeutic use, thrombolytic drugs 血栓溶解药的有害效应
Conclusion:Both fibrinolytic enzyme and urokinase were effective , reliable thrombolytic drugs in the treatment of ADVT,. However , fibrinolytic enzyme showed significantly better security than that of urokinase in thrombolytic therapy.
结论:蛇毒纤溶酶和尿激酶都是治疗急性下肢深静脉形成疗效肯定、安全的溶栓药物,蛇毒纤溶酶安全性高于尿激酶。
参考来源 - 蛇毒纤溶酶与尿激酶治疗急性下肢深静脉血栓形成临床对比观察·2,447,543篇论文数据，部分数据来源于NoteExpress
OBJECTIVE: To introduce the research and development of thrombolytic drugs for AMI, and evaluate their clinical efficacy and safety.
目的：介绍急性心肌梗死溶栓药物的研发进展，并评价其临床疗效和安全性。
Thrombolytic therapy is restricted to the time-window, while neuroprotective drugs, despite its unlimited time constraints, are also stuck.
溶栓治疗有时间限制，而无时间限制的神经保护治疗也陷入了困境。
应用推荐